Word

TICEBA STEM CELL EXPERTS

Status

Registered

Status Code

700

Status Date

Tuesday, October 4, 2022

Serial Number

79311207

Registration Number

6861489

Registration Date

Tuesday, October 4, 2022

Mark Type

4000

Filing Date

Tuesday, December 22, 2020

Published for Opposition

Tuesday, July 19, 2022

Trademark Owner History

Dr. Christoph Ganss - Original Registrant

Classifications

5 pharmaceutical drugs, namely pharmaceutical drugs for treatment of skin diseases, antibiotics, immune suppressants, anti-inflammatory pharmaceuticals; pharmaceutical drugs for treatment of disease and disorders of the respiratory system, the gastrointestinal system, the endocrine system, the cardiovascular system, the nervous system, the musculoskeletal system, the urinary system, the integumentary system, the reproductive system, for the treatment of blood diseases and disorders; pharmaceutical drugs for treatment of cancer, hormone replacement therapy preparations; pharmaceutical and veterinary preparations for treatment of vertigo, migraine, nausea, vomiting, for treatment of skin diseases, wound healing, pharmaceutical and veterinary preparations for treating diabetes, antidepressants; pharmaceutical preparations for anti-aging, pharmaceutical preparations namely antibiotics, vaccines; diagnostic agents for medical use; preparations for medical purposes, namely, for the treatment of skin diseases, allergy medication, herbal extracts for medical use, reagents for medical use; substances for medical use, namely, for regeneration of tissue and anti-inflammation; stem cells for medical purposes; stem cells for veterinary purposes; stem cells for aesthetic purposes, namely, for anti-aging, for use in dermatology procedures; somatic stem cell therapeutics, namely, for medical therapeutic use; fibroblasts for medical use; fibroblasts for aesthetic purposes, namely, for use in dermatology procedures; pharmaceutical implants, namely, implantable subcutaneous drug delivery devices sold filled with pharmaceutical for treatment of skin diseases, blood diseases, vertigo, nausea, vomiting, migraine, respiratory system, the gastrointestinal system, the endocrine system, the cardiovascular system, the musculoskeletal system, the urinary system, the integumentary system, and the reproductive system; surgical implants derived from stem cells, namely, surgical implants derived from living tissues and living stem cells; surgical implants derived from fibroblasts, namely, surgical implants comprised of living fibroblasts tissue cells; biological tissue for implantation, namely, implants comprising living tissues; cell growth media for growing cells for medical use; pharmaceutical preparations for tissue regeneration; vascular grafts; living tissue, namely, surgical implants comprised of living tissues; biotechnologically engineered tissue products, namely, living tissue cell sheets and plasters for wound healing and burns, biological eye lens grafts, bone grafts in the nature of biological bone tissue for grafting, biological tissue grafts, human allograft tissue

1 Stem cells for scientific or research use; cell growth media for growing cells for scientific use

44 Medical services relating to the removal, treatment, processing and preservation of human blood, cord blood, human cells and tissue, stem cells and bone marrow, also in the field of regenerative medicine, including tissue engineering; medical services in connection with the removal, treatment and processing of human tissue and stem cells, human tissue and stem cell bank services, including in the field of regenerative medicine, including tissue engineering; medical services relating to the cultivation and extraction of stem cells; medical services in connection with the cultivation and extraction of stem cells

42 Stem cell research; scientific research and development and medical research and development in the field of stem cells, vaccines and medications; scientific research, testing and analysis services in the field of regenerative medicine and tissue engineering, genetics and genetic engineering; scientific research for medical purposes; medical research; research and development of new products for others; consultancy in the field of pharmaceutical research; providing information on medical and scientific research on pharmaceutical products; biomedical research; preparation of reports relating to scientific research, namely, technical writing for others; research in the field of biotechnology; research in the field of gene therapy; research and development in the field of immunology; research and development in the field of antibodies; research and development in the field of antibody technology; research and development in the field of bacteriology; research and development in the field of gene expression systems; research and development in the field of vaccines; research and development services for the pharmaceutical industry; research and development services in the field of biotechnology; development of industrial processes, namely, engineering of industrial processes in the field of for packaging, storage and transport of human tissue and human adult ancestral cells, engineering of industrial processes to manufacture stem cells; industrial process research in the field of regenerative medicine and tissue engineering, chemical engineering

"STEM CELL EXPERTS"

Trademark Events

Feb 20, 2023

Final Decision Transaction Processed By Ib

Jan 26, 2023

Final Disposition Notice Sent To Ib

Jan 26, 2023

Final Disposition Processed

Jan 4, 2023

Final Disposition Notice Created, To Be Sent To Ib

Oct 4, 2022

Notice Of Registration Confirmation Emailed

Oct 4, 2022

Registered-Principal Register

Jul 25, 2022

Notification Processed By Ib

Jul 19, 2022

Official Gazette Publication Confirmation E-Mailed

Jul 19, 2022

Published For Opposition

Jun 29, 2022

Notification Of Possible Opposition Sent To Ib

Jun 29, 2022

Notice Of Start Of Opposition Period Created, To Be Sent To Ib

Jun 29, 2022

Notification Of Notice Of Publication E-Mailed

Jun 15, 2022

Approved For Pub - Principal Register

Jun 9, 2022

Teas/Email Correspondence Entered

Jun 8, 2022

Correspondence Received In Law Office

Jun 8, 2022

Teas Request For Reconsideration Received

Dec 22, 2021

Notification Of Final Refusal Emailed

Dec 22, 2021

Final Refusal E-Mailed

Dec 22, 2021

Final Refusal Written

Dec 21, 2021

Teas/Email Correspondence Entered

Dec 20, 2021

Correspondence Received In Law Office

Dec 20, 2021

Teas Response To Office Action Received

Jul 19, 2021

Refusal Processed By Ib

Jun 28, 2021

Non-Final Action Mailed - Refusal Sent To Ib

Jun 28, 2021

Refusal Processed By Mpu

Jun 18, 2021

Non-Final Action (Ib Refusal) Prepared For Review

Jun 17, 2021

Non-Final Action Written

Jun 16, 2021

Assigned To Examiner

May 25, 2021

Application Filing Receipt Mailed

May 21, 2021

New Application Office Supplied Data Entered

May 20, 2021

Sn Assigned For Sect 66a Appl From Ib